Scarica l'app Stockscreener
29.24
3.36%
0.95
Dopo l'orario di chiusura:
29.41
0.17
+0.58%
Faeth Therapeutics Inc Borsa (FTH) Ultime notizie
Oppenheimer initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 23, 2026 - marketscreener.com
Faeth Therapeutics Ord Shs (FTH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FTH|Faeth Therapeutics Ord Shs|Price:28.290|Chg%:+0.530 - TradingKey
Faeth Therapeutics Adopts Performance-Based Stock Option Plan - TipRanks
Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver - TradingView
Faeth Therapeutics (FTH) grants CEO 398,018 performance-based options - Stock Titan
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
FTH Initiated Coverage by Citizens -- Price Target Announced at $51 - GuruFocus
Faeth Therapeutics initiated with an Outperform at Citizens - TipRanks
Citizens initiates Faeth Therapeutics stock at outperform, $51 target By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Intuitive Surgical (ISRG) and Faeth Therapeutics (FTH) - The Globe and Mail
Citi Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
FTH Reiterated by BTIG -- Price Target Maintained at $55 - GuruFocus
Issuance/retirement of debt (net) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Faeth Therapeutics, Inc trading resumes - TipRanks
A Closer Look At Faeth Therapeutics' PIKTOR - RTTNews
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
Faeth’s PIKTOR Trial Targets Advanced Breast Cancer With a New Combo Approach - TipRanks
BTIG Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock - Investing.com India
Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock By Investing.com - Investing.com Australia
Faeth Therapeutics (FTH) CFO adds 13,634 shares via trust purchases - Stock Titan
Form 4 Faeth Therapeutics, Inc For: 1 July By Investing.com - Investing.com India
FTHFaeth Therapeutics Inc Latest SEC Filings - Finviz
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Value Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Growth Benchmark - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell Microcap Index - marketscreener.com
Faeth Therapeutics, Inc.(NasdaqCM: FTH) added to Russell 3000E Value Benchmark - marketscreener.com
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock By Investing.com - Investing.com UK
Total current assets of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Form 4 Faeth Therapeutics, Inc For: 26 June By Investing.com - Investing.com Australia
Faeth Therapeutics CFO Stephenson acquires $401,268 in stock - Investing.com
Faeth Therapeutics (FTH) CFO adds 15,641 shares via trust purchases - Stock Titan
FTH Initiates Coverage On Faeth Therapeutics -- Price Target Set at $57 - GuruFocus
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Baird Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $57 - Moomoo
Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target - marketscreener.com
Enterprise value to revenue forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Enterprise value to EBIT forward of Faeth Therapeutics, Inc. – MUN:4070 - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Price to sales forward of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Baird initiates Faeth Therapeutics stock with outperform rating - Investing.com
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):